China has become the base of Japanese and Korean traditional Chinese medicine: 90% market share is monopolized by it

At the end of the year, Britain once again began to struggle with traditional Chinese medicine Since the strict implementation of EU regulations in the UK, no one of the more than 200 Chinese patent medicines sold in the UK has been successfully registered, which also means that after April 30, 2014, all the stocks of Chinese patent medicines in the UK market will be removed Previously, according to the report on pesticide residues of traditional Chinese medicine in overseas markets released by Greenpeace, the international environmental protection organization, samples of Chinese medicine products from seven countries, including the United States and the United Kingdom, were tested and found to contain a variety of pesticide residues Nine Chinese medicine brands, including Tongrentang, Yunnan Baiyao, Hu qingyutang and Tianshi, were shot one after another However, so far, Chinese medicine enterprises have not made effective response to overseas market to alleviate the trust crisis of Chinese medicine in overseas market There is a long way to go At the same time, Japan, South Korea, the United States and other countries, while the overseas market of domestic traditional Chinese medicine enterprises is blocked, have made huge profits by processing raw materials of crude Chinese medicine imported from China into Chinese patent medicine in large quantities At present, it is recognized that foreign enterprises such as South Korea, Japan and the United States directly monopolize about 90% of the international market share of Chinese patent medicine China becomes the base of Japanese and Korean traditional Chinese medicine? In the world market of traditional Chinese medicine, Japan and South Korea account for 80% ~ 90% of the market share, and 75% of raw materials for the production of Japanese traditional Chinese medicine preparations are imported from China The domestic traditional Chinese medicine enterprises have called for "internationalization of traditional Chinese medicine" for many years or are evolving into "internationalization of traditional Chinese medicine" It is understood that at present, the annual sales volume of the world's proprietary Chinese medicine market has reached more than 30 billion US dollars, while China, which has the absolute advantage of Chinese medicine resources in the world, only accounts for 5% of the share According to the national pharmaceutical foreign trade situation conference held recently, at present, the annual scale of China's traditional Chinese medicine industry has reached more than 410 billion yuan, but the export of traditional Chinese medicine products in 2012 was only 2.499 billion US dollars Among them, the export of Chinese herbal medicines and pieces of decoction was $858 million, the export of Chinese patent medicine was only $265 million, and the export of extracts was $1164 million The international export of Chinese patent medicine is still facing difficulties, and there is a deficit of 3 million US dollars again In the world market of traditional Chinese medicine, Japan and South Korea account for 80% ~ 90% of the market share, and 75% of the raw materials for the production of Japanese traditional Chinese medicine preparations are imported from China These countries import raw materials of crude processing Chinese medicine from China and then finish processing, and then make tablets and capsules that meet international standards In view of the fact that the internationalization of traditional Chinese medicine has far exceeded that of traditional Chinese medicine, Anguo, one of the four major pharmaceutical capitals in China, has held an international Chinese medicine festival every year Xu, who is responsible for building the exhibition platform, told China business daily (Weibo) that by 2015, Anguo's exports of Chinese herbal medicines will reach 50 million US dollars, 80% of which are pharmaceutical companies selling to Japan, South Korea and other countries According to statistics, at present, Japan is the largest producer and consumer of traditional Chinese medicine besides China Today, there are more than 200 Chinese medicine factories in Japan Prescription Chinese medicine grows at a rate of 15% every year, with annual sales reaching US $1.5 billion There are about 148 kinds of Chinese medicine approved by the Japanese government to apply the "national health insurance system" At present, the annual output value of Chinese medicine in Japan has exceeded 100 billion yen In the trade of Chinese patent medicine and Chinese medicine health care products in the international market, Japanese production accounts for a large share Jincun pharmaceutical, Japan's largest Chinese pharmaceutical company, is China's biggest competitor in the internationalization of Chinese patent medicines, a long-term industry insider who has paid close attention to the overseas market of traditional Chinese medicine told reporters This enterprise established Shanghai Jincun Pharmaceutical Co., Ltd in 2001 and applied for FDA in 2005 Both in Japan and the United States, Jincun has established a very stable market position Since the 1990s, the development of Korean traditional Chinese medicine industry has been strong At present, traditional Chinese medicine accounts for 15% of the national medical expenditure in South Korea, which is second only to China Compared with China's traditional Chinese medicine, which focuses on raw material planting, it has standardized processing and operation, strict standards, and in place packaging and publicity The unit price of the same level of reference products is 25 times that of China Westernization or adherence to tradition? There are still controversies in the field of imitating Japan and South Korea and sticking to tradition For Jincun pharmaceutical industry, domestic traditional Chinese medicine enterprises are not new About 80% of Chinese herbal medicines need to be imported from China Jincun pharmaceutical industry has established more than 70 gap planting bases in China In the aspect of basic research, Jincun pharmaceutical industry also invests a lot of human and material resources in the research of pharmacology, toxicology, standardization and standardization of dosage form component analysis After inheriting the essence of traditional Chinese medicine, Jincun pharmaceutical industry scientifically integrates it with western medicine On the other hand, the domestic traditional Chinese medicine enterprises are far inferior to the layout of Jincun pharmaceutical industry in terms of the source of the base of traditional Chinese medicine Tongrentang has carried out the layout of herbal medicine planting base more than ten years ago At present, Tongrentang has 8 gap bases in China, which is the most Chinese medicine enterprise with gap bases in China However, compared with more than 70 bases in Jincun pharmaceutical industry, it is quite different Guanying copper, a researcher from the prospective industry research institute, told our reporter that China's traditional Chinese medicine industry must improve its quality standards and safety access system, which may be one of the ways to solve the safety problems of traditional Chinese medicine, while increasing gap construction is the top priority of the source On the way to test water overseas, Chinese pharmaceutical companies are not as smooth as Jincun pharmaceutical For more than 20 years, many well-known Chinese medicine enterprises have been testing overseas, and most of the huge capital invested in the overseas market is in the initial stage The export of traditional Chinese medicine by the top three nine groups and Tongrentang is also limited to the Chinese circle However, in recent years, some Chinese medicine enterprises have made some progress in their efforts to break the entry threshold of overseas markets At present, China has 10 kinds of traditional Chinese medicine prescription drugs, such as compound Danshen dropping pills and zhizhikang, formally applied to the US FDA for testing and certification Seven of them have entered phase II clinical trials, and the other three are starting phase I clinical trials At the beginning of November, Fuzheng Huayu tablet successfully completed the second phase of clinical trial in the United States, which also encouraged the domestic traditional Chinese medicine enterprises However, there are still disputes in the field of imitating Japan and South Korea and sticking to tradition Yu Zhibin, deputy director of traditional Chinese Medicine Department of China Chamber of Commerce for the import and export of health care products (21.61, 0.13, 0.61%), disagreed with the share of 5% of the export of traditional Chinese medicine in the overseas market He said that traditional Chinese medicine, including various products such as Chinese herbal pieces, Chinese herbal medicines, Chinese patent medicines and so on, has different calculation caliber in different countries, and there is no unified official data around the world As for the internationalization of traditional Chinese medicine, Yu Zhibin believes that it is up to China to formulate standards in accordance with the culture of traditional Chinese medicine, rather than the way of Western medicine He expressed admiration for and did not support all the enterprises to do so "Obviously, too high clinical cost will hinder the process of internationalization of traditional Chinese medicine." Yu Zhibin said that Chinese people have taken traditional Chinese medicine for thousands of years and have hard won clinical experience At present, the difficulty of internationalization of traditional Chinese medicine is mainly based on the overseas ignorance of traditional Chinese medicine culture In the future, traditional Chinese medicine should follow the way when western medicine entered China, take traditional Chinese medicine abroad, and go abroad together with traditional Chinese medicine "The internationalization of traditional Chinese medicine in the future will inevitably be the integration process of pharmaceutical industry trade and service trade."